60 Degrees Pharmaceuticals Receives FDA Comments On Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required, Trial Planning And Execution To Proceed As Planned
60 Degrees Pharmaceuticals Receives FDA Comments On Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required, Trial Planning And Execution To Proceed As Planned
60 Degrees Pharmicals收到美国食品药品管理局对他非诺喹-巴贝斯虫病临床试验方案的评论；无需进行实质性更改，试验计划和执行按计划进行
60 Degrees Pharmaceuticals Receives FDA Comments On Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required, Trial Planning And Execution To Proceed As Planned
60 Degrees Pharmicals收到美国食品药品管理局对他非诺喹-巴贝斯虫病临床试验方案的评论；无需进行实质性更改，试验计划和执行按计划进行
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。